Kiora Pharmaceuticals, Inc.
KPRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $16,000 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $16,000 | $0 | $0 | $0 |
| % Margin | 100% | – | – | – |
| R&D Expenses | $4,897 | $4,027 | $3,449 | $5,350 |
| G&A Expenses | $5,542 | $4,663 | $8,278 | $5,324 |
| SG&A Expenses | $5,542 | $4,663 | $8,278 | $5,324 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1,051 | $3,897 | $583 | $3,562 |
| Operating Expenses | $11,490 | $12,587 | $12,310 | $14,236 |
| Operating Income | $4,510 | -$12,587 | -$12,310 | -$14,236 |
| % Margin | 28.2% | – | – | – |
| Other Income/Exp. Net | $1,149 | $163 | -$1,387 | $272 |
| Pre-Tax Income | $5,660 | -$12,424 | -$13,697 | -$13,963 |
| Tax Expense | $2,065 | $90 | -$113 | -$193 |
| Net Income | $3,595 | -$12,514 | -$13,584 | -$13,771 |
| % Margin | 22.5% | – | – | – |
| EPS | 0.93 | -24.25 | -18.55 | -68 |
| % Growth | 103.8% | -30.7% | 72.7% | – |
| EPS Diluted | 0.87 | -24.25 | -18.55 | -68 |
| Weighted Avg Shares Out | 3,873 | 538 | 732 | 241 |
| Weighted Avg Shares Out Dil | 4,125 | 538 | 732 | 241 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,253 | $174 | $57 | $1 |
| Interest Expense | $21 | $11 | $9 | $7 |
| Depreciation & Amortization | $19 | $52 | $42 | $45 |
| EBITDA | $5,700 | -$12,361 | -$13,646 | -$13,911 |
| % Margin | 35.6% | – | – | – |